肝炎のはなし

出版社： 朝倉書店
著者：
発行日： 2021-07-01
分野： 臨床医学：内科  >  肝/胆/膵
ISBN： 9784254310955
電子書籍版： 2021-07-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

2,970 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,970 円(税込)

購入する

商品紹介

肝臓病学の第一人者が巨大感染症の発見と克服の歴史をわかりやすく解説。

目次

  • 第1章　C型肝炎ウイルスの発見
    第2章　ウイルスの発見がもたらしたこと
    　　　　―疾患と理解と予防法の確立
    第3章　C型肝炎のインターフェロン治療
    第4章　DAAの時代
    　　　　―直接作用する抗ウイルス薬
    第5章　DAAがもたらした「新しい肝臓像」
    第6章　これからの肝疾患

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

参考文献

P.141 掲載の参考文献
Alter HJ, et al : Clinical and serological analysis of transfusion-associated hepatitis. Lancet. 1975 ; 2 (7940) : 838-841.
PubMed
Hoofnagle JH, et al : Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 ; 315 (25) : 1575-1578.
PubMed
Choo QL, et al : Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 ; 244 (4902) : 359-362.
 
Kuo G, et al : An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 ; 244 (4902) : 362-364.
 
Kato N, et al : Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A. 1990 ; 87 (24) : 9524-9528.
PubMed
Takamizawa A, et al : Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol. 1991 Mar ; 65 (3) : 1105-1113.
 
Choo QL, et al : Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A. 1991 ; 88 (6) : 2451-2455.
PubMed
Kato N, et al : Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest. 1990 ; 86 (5) : 1764-1767.
PubMed
Chayama K, et al : Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology. 1991 ; 13 (6) : 1040-1043.
PubMed
Hagiwara H, et al : Detection of hepatitis C virus RNA in chronic non-A, non-B liver disease. Gastroenterology. 1992 ; 102 (2) : 692-694.
 
Hagiwara H, et al : Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993 ; 104 (3) : 877-883.
PubMed
Kiyosawa K, et al : Natural history of hepatitis C. Intervirology. 1994 ; 37 (2) : 101-107.
PubMed
Enomoto N, et al : There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun. 1990 ; 170 (3) : 1021-1025.
PubMed
Zein NN : Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000 ; 13 (2) : 223-235.
PubMed
Simmonds P, et al : Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005 ; 42 (4) : 962-973.
PubMed
Enomoto N, et al : Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996 ; 334 (2) : 77-81.
PubMed
Kolykhalov AA, et al : Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997 ; 277 (5325) : 570-574.
PubMed
Kasahara A, et al : Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998 ; 27 (5) : 1394-1402.
 
Yoshida H, et al : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999 ; 131 (3) : 174-181.
 
Shiratori Y, et al : Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000 ; 132 (7) : 517-524.
PubMed
Hayashi N, et al : Antiviral therapy for chronic hepatitis C : past, present, and future. J Gastroenterol. 2006 ; 41 (1) : 17-27.
PubMed
Mizokami T, et al : Tracing the evolution of hepatitis C virus in the United States, Japan, and Egypt by using the molecular clock. Clin Gastroenterol Hepatol. 2005 ; 3 (10 Suppl 2) : S82-85.
 
Tanaka Y, et al : Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009 ; 41 (10) : 1105-1109.
PubMed
Thomas DL, et al : Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009 ; 461 (7265) : 798-801.
PubMed
Urban TJ, et al : IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010 ; 52 (6) : 1888-1896.
PubMed
Honda M, et al : Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010 ; 139 (2) : 499-509.
PubMed
Fellay J, et al : ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010 ; 464 (7287) : 405-408.
PubMed
Hitomi Y, et al : Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology. 2011 ; 140 (4) : 1314-1321.
PubMed
Khakoo SI, et al : HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004 ; 305 (5685) : 872-874.
PubMed
Kolykhalov AA, et al : Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997 ; 277 (5325) : 570-574.
PubMed
Lohmann V, et al : Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999 ; 285 (5424) : 110-113.
 
Yokota T, et al : Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003 ; 4 (6) : 602-608.
PubMed
Wakita T, et al : Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005 ; 11 (7) : 791-796.
PubMed
Yao N, et al : Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure. 1999 ; 7 (11) : 1353-1363.
PubMed
Lesburg CA, et al : Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 1999 ; 6 (10) : 937-943.
PubMed
Reesink HW, et al : Rapid decline of viral RNA in hepatitis C patients treated with VX-950 : a phase Ib, placebo-controlled, randomized study. Gastroenterology. 2006 ; 131 (4) : 997-1002.
PubMed
Sarrazin C, et al : Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007 ; 132 (5) : 1767-1777.
PubMed
Kumada H, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014 ; 59 (6) : 2083-2091.
PubMed
Mizokami M, et al : Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015 ; 15 (6) : 645-653.
PubMed
Uchida Y, et al : Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res. 2016 ; 46 (12) : 1234-1246.
PubMed
Doi A, et al : Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology. 2018 ; 68 (1) : 380-383.
PubMed
Hikita H, et al : NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors. Semin Liver Dis. 2020 ; 40 (2) : 143-153.
PubMed
Izumi N, et al : Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018 ; 12 (4) : 356-367.
 
Uemura H, et al : NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019 ; 54 (5) : 459-470.
PubMed
Tahata Y, et al : Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment. Hepatol Res. 2020 ; 50 (3) : 313-320.
 
Perez S, et al : Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019 ; 15 (6) : e1008181.
PubMed
Younossi Z, et al : Extrahepatic Manifestations of Hepatitis C : A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016 ; 150 (7) : 1599-1608.
PubMed
Saito T, et al : Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature. 2008 ; 454 (7203) : 523-527.
PubMed
Fattovich G, et al : Hepatocellular carcinoma in cirrhosis : incidence and risk factors. Gastroenterology. 2004 ; 127 (5 Suppl 1) : S35-50.
 
FDA Drug Safety Communication : FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. [https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-risk-hepatitis-b-reactivating-some-patients-treated] (2021年2月12 日閲覧)
 
Doi A, et al : Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals : Analysis of a Japanese prospective cohort. Hepatol Res. 2017 ; 47 (13) : 1438-1444.
PubMed
Murai H, et al : Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathway. Sci Rep. 2020 ; 10 (1) : 941.
 
Di Marco V, et al : Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Gastroenterology. 2016 ; 151 (1) : 130-139.e2.
 
Takehara T, et al : Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol. 2019 ; 54 (1) : 87-95.
 
Tahata Y, et al : Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis : a Japanese real-world multicenter study. J Gastroenterol. 2021 ; 56 (1) : 67-77.
PubMed
Maesaka K, et al : Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res. 2021 Jan 28. doi : 10.1111/hepr.13623. Online ahead of print.
 
Tateishi R, et al : A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan : 2011-2015 update. J Gastroenterol. 2019 ; 54 (4) : 367-376.
PubMed
World Health Organization : Global health sector strategy on viral hepatitis 2016-2021 : towards ending viral hepatitis. 2016. [https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1] (2021年2月閲覧)
 
Polaris Observatory HCV Collaborators : Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : a modelling study. Lancet Gastroenterol Hepatol. 2017 ; 2 (3) : 161-176.
PubMed
日本肝臓学会 : 特集 C型肝炎ウイルスの発見から撲滅への道. 日本肝臓学会雑誌. 2021 ; 62 (4) : 183-223. [https://www.jstage.jst.go.jp/browse/kanzo/62/4/_contents/-char/ja] (2021年5月閲覧)
 

書評

最近チェックした商品履歴

Loading...